Immix Biopharma, Inc. (IMMX) stock
IMMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.20−0.28 (-3.74%)
Close on Nov 17, 2026Market cap $515.08MP/E –Yield –
Immix Biopharma r&d expenses
Research and development expenses are spending on new products and technology.
Immix Biopharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $21.62M, up 83.8% year over year. For fiscal 2025 it was $16.26M, up 44.0% from the year before. The highest annual figure on record is $16.26M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.26M | +44.0% |
| FY2024 | Dec 31, 2024 | $11.29M | +29.3% |
| FY2023 | Dec 31, 2023 | $8.74M | +108.2% |
| FY2022 | Dec 31, 2022 | $4.20M | +3216.1% |
| FY2021 | Dec 31, 2021 | $126.53K | -49.0% |
| FY2020 | Dec 31, 2020 | $248.15K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.33M | +34.3% |
| Q1 FY2026 | Mar 31, 2026 | $5.98M | +202.8% |
| Q4 FY2025 | Dec 31, 2025 | $5.73M | +316.7% |
| Q3 FY2025 | Sep 30, 2025 | $4.58M | +3.1% |
| Q2 FY2025 | Jun 30, 2025 | $3.97M | +78.6% |
| Q1 FY2025 | Mar 31, 2025 | $1.98M | -39.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.37M | -55.7% |
| Q3 FY2024 | Sep 30, 2024 | $4.45M | +111.1% |
| Q2 FY2024 | Jun 30, 2024 | $2.22M | +0.7% |
| Q1 FY2024 | Mar 31, 2024 | $3.25M | +146.3% |
| Q4 FY2023 | Dec 31, 2023 | $3.10M | +37.0% |
| Q3 FY2023 | Sep 30, 2023 | $2.11M | +202.6% |
| Q2 FY2023 | Jun 30, 2023 | $2.21M | +263.5% |
| Q1 FY2023 | Mar 31, 2023 | $1.32M | +109.5% |
| Q4 FY2022 | Dec 31, 2022 | $2.26M | +24397.2% |
| Q3 FY2022 | Sep 30, 2022 | $695.94K | +2244.0% |
| Q2 FY2022 | Jun 30, 2022 | $607.75K | +868.4% |
| Q1 FY2022 | Mar 31, 2022 | $629.53K | +2434.3% |
| Q4 FY2021 | Dec 31, 2021 | $9.24K | – |
| Q3 FY2021 | Sep 30, 2021 | $29.69K | – |
| Q2 FY2021 | Jun 30, 2021 | $62.76K | – |
| Q1 FY2021 | Mar 31, 2021 | $24.84K | – |
See a number that looks wrong?